Great improvement in the treatment of patients with aggressive non-Hod
gkin's lymphoma (NHL) has been obtained with the introduction of new c
ombination chemotherapy regimens in the 1970s. The hope that there wou
ld be further improvement has waned during recent years due to the fac
t that some controlled studies did not reveal any better results using
the new more intensive treatment regimens. This is the reason for the
question: are we doing any better?